---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-113659"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T06:19:57.156857+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA approves Emrosi for rosacea; Q3 prelim revenue $14.6M, net loss $2.4M; FY guidance unchanged

## Summary
- FDA approved Emrosi (minocycline HCl ER 40 mg) for inflammatory lesions of rosacea in adults; initial supply expected late Q1 or early Q2 2025.
- Q3 2024 prelim net product revenue $14.6M (vs $15.3M YoY); net loss $2.4M (vs $16.8M net income Q3 2023 which had $19.3M license payment).
- Nine-month 2024 net product revenue $42.5M (vs $44.4M); net loss $16.2M (vs $1.7M); R&D $9.6M includes $4.1M FDA fee and $3.0M milestone to DRL.
- FY 2024 guidance unchanged: net revenue $55-60M, SG&A $39-42M, R&D $9-10M.
- Approval triggered $15M milestone to Dr. Reddy's; mandatory $5M draw under SWK Credit; expects $4.4M recovery from 2021 cyber incident in Q4.

## SEC filing metadata
- accession: 0001104659-24-113659
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465924113659/0001104659-24-113659-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465924113659/tm2427383d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-113659
- JSON: https://secwatch.observer/filing/0001104659-24-113659.json
- Plain text: https://secwatch.observer/filing/0001104659-24-113659.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.